Literature DB >> 16872721

Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.

Christian Freichel1, Manuela Neumann, Theresa Ballard, Veronika Müller, Marie Woolley, Laurence Ozmen, Edilio Borroni, Hans A Kretzschmar, Christian Haass, Will Spooren, Philipp J Kahle.   

Abstract

Intraneuronal alpha-synuclein (alphaSYN) inclusions constitute the hallmark lesions of a number of neurodegenerative diseases, including Parkinson's disease and dementia with Lewy bodies. In a transgenic mouse model expressing mutant [A30P]alphaSYN under control of the pan-neuronal Thy1 promoter, motor impairment became significant beyond 17 months of age. Cognitive performance was measured in the Morris water maze and upon fear conditioning. At 4 months of age, transgenic mice performed like controls. However, performance in these tasks was significantly impaired in (Thy1)-h[A30P]alphaSYN mice at 12 months of age. After completion of the cognition tests, mice were sacrificed and the regional distribution of neuropathology was examined. In contrast to 4 months old animals, 12 months old transgenic mice showed alpha-synucleinopathy in several brain regions, including the central nucleus of the amygdala, which is involved in cognitive behavior of mice, and is susceptible to alphaSYN pathology in human patients. Thus, age-dependent fibrillization of alphaSYN in specific cortical regions concomitant with cognitive decline may reflect dementia with Lewy bodies in a transgenic mouse model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16872721     DOI: 10.1016/j.neurobiolaging.2006.06.013

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  63 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Authors:  Lani K Clinton; Mathew Blurton-Jones; Kristoffer Myczek; John Q Trojanowski; Frank M LaFerla
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

4.  α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.

Authors:  Zane S Martin; Volker Neugebauer; Kelly T Dineley; Rakez Kayed; Wenru Zhang; Lindsay C Reese; Giulio Taglialatela
Journal:  J Neurochem       Date:  2011-11-28       Impact factor: 5.372

5.  Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse.

Authors:  Isin Unal-Cevik; Yasemin Gursoy-Ozdemir; Muge Yemisci; Sevda Lule; Gunfer Gurer; Alp Can; Veronica Müller; Philip J Kahle; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

Review 6.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

7.  Phosphorylation of synucleins by members of the Polo-like kinase family.

Authors:  Martial K Mbefo; Katerina E Paleologou; Ahmed Boucharaba; Abid Oueslati; Heinrich Schell; Margot Fournier; Diana Olschewski; Guowei Yin; Markus Zweckstetter; Eliezer Masliah; Philipp J Kahle; Harald Hirling; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

8.  Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.

Authors:  Kelly J Inglis; David Chereau; Elizabeth F Brigham; San-San Chiou; Susanne Schöbel; Normand L Frigon; Mei Yu; Russell J Caccavello; Seth Nelson; Ruth Motter; Sarah Wright; David Chian; Pamela Santiago; Ferdie Soriano; Carla Ramos; Kyle Powell; Jason M Goldstein; Michael Babcock; Ted Yednock; Frederique Bard; Guriqbal S Basi; Hing Sham; Tamie J Chilcote; Lisa McConlogue; Irene Griswold-Prenner; John P Anderson
Journal:  J Biol Chem       Date:  2008-11-12       Impact factor: 5.157

9.  Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.

Authors:  Natalia Ninkina; Owen Peters; Steven Millership; Hatem Salem; Herman van der Putten; Vladimir L Buchman
Journal:  Hum Mol Genet       Date:  2009-02-26       Impact factor: 6.150

10.  Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.

Authors:  Margot Fournier; Jérémie Vitte; Jérôme Garrigue; Dominique Langui; Jean-Philippe Dullin; Françoise Saurini; Naïma Hanoun; Fernando Perez-Diaz; Fabien Cornilleau; Chantal Joubert; Héctor Ardila-Osorio; Sabine Traver; René Duchateau; Cécile Goujet-Zalc; Katerina Paleologou; Hilal A Lashuel; Christian Haass; Charles Duyckaerts; Charles Cohen-Salmon; Philipp J Kahle; Michel Hamon; Alexis Brice; Olga Corti
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.